Literature DB >> 8885850

HIV-1 membrane fusion mechanism: structural studies of the interactions between biologically-active peptides from gp41.

M K Lawless1, S Barney, K I Guthrie, T B Bucy, S R Petteway, G Merutka.   

Abstract

Two synthetic peptides corresponding to sequences in HIV-1LAI gp41, (aa558-595) and T20 (aa 643-678), are strong inhibitors of HIV-1 viral fusion, having EC50 values of 1 microgram/mL and 1 ng/mL, respectively. Previous work suggested that T21 forms a coiled-coil structure in PBS solution, while T20 is primarily nonhelical, and that the inhibitory action of these peptides occurs after the interaction between the viral gp120 protein and the cellular CD4 receptor [Wild, C.T., Shugars, D. C., Greenwell, T. K., McDanal, C. B., Matthews, T. J. (1994) Proc. Natl. Acad. Sci. U.S.A. 91, 9770 and references therein]. The current study uses sedimentation equilibrium (SE), circular dichroism (CD), and viral-fusion assays to quantitatively investigate peptide structure and peptide-peptide interactions. SE analyses of T21 (1-100 microM) indicate that the peptide self associates via a monomer/dimer/tetramer equilibrium; in addition, T20 is monomeric in the range of 1-10 microM and exhibits a complicated monomer/tetramer equilibrium between 20 and 100 microM. Singular value decomposition analyses of the CD spectra of T21 and T20 indicate that the helical content of these peptides in PBS solution is 90% and 20%, respectively. A structural interaction between the two peptides is detected by CD at several concentration ratios of T20:T21. These experiments emphasize that T20 interacts specifically with the tetrameric form of T21. Truncated forms of T20 also exhibit structural interactions with T21 at varying concentration ratios. The ability of T20 and the truncated peptides to interact structurally with tetrameric T21 correlates with antiviral activity. Implications of these findings are discussed in terms of proposed mechanisms of membrane fusion inhibition and the structural changes which occur in gp41 during membrane fusion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8885850     DOI: 10.1021/bi9606962

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  55 in total

1.  The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil.

Authors:  J M Matthews; T F Young; S P Tucker; J P Mackay
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Trimeric, coiled-coil extension on peptide fusion inhibitor of HIV-1 influences selection of resistance pathways.

Authors:  Min Zhuang; Wei Wang; Christopher J De Feo; Russell Vassell; Carol D Weiss
Journal:  J Biol Chem       Date:  2012-01-10       Impact factor: 5.157

3.  Interactions between different generation HIV-1 fusion inhibitors and the putative mechanism underlying the synergistic anti-HIV-1 effect resulting from their combination.

Authors:  Lifeng Cai; Chungen Pan; Liang Xu; Yuan Shui; Keliang Liu; Shibo Jiang
Journal:  FASEB J       Date:  2011-11-15       Impact factor: 5.191

4.  The appealing story of HIV entry inhibitors : from discovery of biological mechanisms to drug development.

Authors:  Antonella Castagna; Priscilla Biswas; Alberto Beretta; Adriano Lazzarin
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  HIV-1 fusion peptide targets the TCR and inhibits antigen-specific T cell activation.

Authors:  Francisco J Quintana; Doron Gerber; Sally C Kent; Irun R Cohen; Yechiel Shai
Journal:  J Clin Invest       Date:  2005-07-07       Impact factor: 14.808

6.  Immunological basis for IgE hyper-production in enfuvirtide-treated HIV- positive patients.

Authors:  Samuele E Burastero; Clara Paolucci; Daniela Breda; Armando Soldarini; Fernanda Dorigatti; Elisa Soprana; Hamid Hasson; Priscilla Biswas; Adriano Lazzarin; Antonella Castagna
Journal:  J Clin Immunol       Date:  2006-04-07       Impact factor: 8.317

7.  Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against enfuvirtide-resistant virus.

Authors:  John J Dwyer; Karen L Wilson; Donna K Davison; Stephanie A Freel; Jennifer E Seedorff; Stephen A Wring; Nicolai A Tvermoes; Thomas J Matthews; Michael L Greenberg; Mary K Delmedico
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-19       Impact factor: 11.205

8.  Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.

Authors:  Kelly Champagne; Akira Shishido; Michael J Root
Journal:  J Biol Chem       Date:  2008-12-10       Impact factor: 5.157

9.  Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41.

Authors:  M B Zwick; A F Labrijn; M Wang; C Spenlehauer; E O Saphire; J M Binley; J P Moore; G Stiegler; H Katinger; D R Burton; P W Parren
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

10.  Apoptosis of bystander T cells induced by human immunodeficiency virus type 1 with increased envelope/receptor affinity and coreceptor binding site exposure.

Authors:  Geoffrey H Holm; Chengsheng Zhang; Paul R Gorry; Keith Peden; Dominique Schols; Erik De Clercq; Dana Gabuzda
Journal:  J Virol       Date:  2004-05       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.